Canada markets closed
  • S&P/TSX

    19,590.74
    +154.76 (+0.80%)
     
  • S&P 500

    4,299.70
    +25.19 (+0.59%)
     
  • DOW

    33,666.34
    +116.07 (+0.35%)
     
  • CAD/USD

    0.7418
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    91.91
    +0.20 (+0.22%)
     
  • Bitcoin CAD

    36,287.54
    +791.91 (+2.23%)
     
  • CMC Crypto 200

    578.20
    +13.41 (+2.37%)
     
  • GOLD FUTURES

    1,881.20
    +2.60 (+0.14%)
     
  • RUSSELL 2000

    1,794.31
    +15.41 (+0.87%)
     
  • 10-Yr Bond

    4.5970
    -0.0290 (-0.63%)
     
  • NASDAQ futures

    14,883.00
    +23.25 (+0.16%)
     
  • VOLATILITY

    17.34
    -0.88 (-4.83%)
     
  • FTSE

    7,601.85
    +8.63 (+0.11%)
     
  • NIKKEI 225

    31,836.24
    -36.28 (-0.11%)
     
  • CAD/EUR

    0.7011
    -0.0005 (-0.07%)
     

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Biomerica, Inc.
Biomerica, Inc.
  • Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for the Rome IV Committee on Functional Bowel Disorders. Dr. Lacy has authored over 225 peer reviewed articles

IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product. InFoods® IBS is the first of its kind diagnostic guided therapy using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of Irritable Bowel Syndrome (IBS) without the use of drugs.

“We have learned throughout decades of research that IBS symptoms can vary dramatically between each patient, so treating IBS using a personalized medicine approach could significantly improve treatment options available to both physicians and their patients,” said Dr. Lacy. “InFoods® IBS is a novel clinically tested therapy that may unlock some of the mysteries surrounding diet and IBS, but more importantly provide relief to the 10-15 percent of American adults who may be suffering from IBS symptoms. I am honored to provide my expertise to Biomerica along with other esteemed members of the Scientific Advisory Board.”

Dr. Lacy's areas of expertise include irritable bowel syndrome, gastroesophageal reflux disease, dysphagia, achalasia, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction and visceral pain. In addition to authoring more than 225 peer-reviewed articles, he also has written multiple textbook chapters and books, including, “Making Sense of IBS”, “Curbside Consultations in IBS”, “Functional and Motility Disorders of the Gastrointestinal Tract” and “Essential Disorders of the Stomach and Small Intestine”. Additionally, Dr. Lacy was the former co-Editor in Chief of the American Journal of Gastroenterology.

“Dr. Lacy is an esteemed researcher who will provide valuable insight and expertise to Biomerica as we get ready to launch our InFoods® IBS laboratory developed test nationwide and expand our clinical development of other InFoods® Technology based products,” said Zack Irani, Chief Executive Officer of Biomerica.

About InFoods®
The Biomerica InFoods® IBS product is designed to allow physicians a new precision medicine approach to identify patient-specific foods (e.g., eggs, broccoli, wheat, potatoes, pork, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, cramping, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a guided dietary regimen to improve IBS outcomes. A point-of-care version of the product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product is expected to be the first for which the Company will launch and seek regulatory approval. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 40 million people in America currently suffer from IBS making it a leading cause for patient doctor visits1.

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the development, validation, FDA clearance and commercial launch of the Company’s products and tests, including products based on the InFoods technology, the Company’s other products and tests, uniqueness of the Company’s products, pricing of the Company’s test kits, demand for domestic or international orders, potential revenues from the sale of current or future products, availability of the Company’s products and other test kits, and patent protection on any of the Company’s products or technologies. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s tests and other products; regulatory approvals necessary prior to commercialization any of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party component manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

1. Canavan et al. The epidemiology of irritable bowel syndrome Clin Epidemiol. 2014; 6: 71–80. doi: 10.2147/CLEP.S40245

Corporate Contact:
Zack Irani
949-645-2111
zirani@biomerica.com

Source: Biomerica